Ze Jing Pharmaceuticals (688266.SH): Injection ZG006 in combination with PD-1/PD-L1 immune checkpoint inhibitors and chemotherapy (Etoposide/Cisplatin) has obtained approval for clinical trials of drug.

Zechuang Pharmaceutical (stock code: 688266.SH) announced that the company has recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (referred to as the "NMPA"). The clinical trial of the injection ZG006 in combination with PD-1/PD-L1 immune checkpoint inhibitors and chemotherapy (etoposide/cisplatin) for small cell lung cancer has been approved. ZG006 (INN name: alveltamig) is a three-specific antibody drug developed by the company through its bispecific/multispecific antibody R&D platform. It has obtained clinical trial permits from the US FDA and China NMPA, and has been included as a breakthrough therapy by the Center for Drug Evaluation of the NMPA, and granted Orphan-drug Designation by the US FDA. ZG006 is a three-specific T cell engager targeting two different DLL3 sites and CD3. ZG006 is the world's first three-specific antibody targeting DLL3 (DLL3/DLL3/CD3), and is the first-in-class molecule globally, with the potential to become the best-in-class molecule. The anti-DLL3 end of ZG006 binds to different DLL3 sites on the surface of tumor cells, while the anti-CD3 end binds to T cells. ZG006 bridges tumor cells and T cells, bringing T cells close to tumor cells, and utilizing T cell-specific killing of tumor cells. Preclinical studies have shown that ZG006 has a significant tumor-inhibiting effect in mouse tumor models, leading to a significant proportion of tumors in mice completely disappearing, indicating its potent tumor-killing effect.